Related Experiment Videos
5th Antiviral Drug Discovery and Development Summit
1Anti-infectives Biology, Sandwich Laboratories, Pfizer Global R&D, Ramsgate Road, Sandwich, Kent, CT13 9PH, UK.
Expert Opinion on Investigational Drugs
|July 23, 2004
Summary
The 5th Antiviral Drug Discovery and Development Summit highlighted new HIV and hepatitis C virus inhibitors. Advances in antiviral targets and technologies promise next-generation therapeutics for these viral diseases.
Area of Science:
- Virology and Pharmaceutical Sciences
- Drug Discovery and Development
Background:
- The 5th Antiviral Drug Discovery and Development Summit convened to present current advancements in antiviral research.
- Focus areas included recently approved drugs and novel investigational inhibitors for viral infections.
Framework:
- The summit explored new classes of human immunodeficiency virus (HIV) inhibitors, targeting gp41 and integrase.
- Significant progress was noted in the development of hepatitis C virus (HCV) inhibitors, with several nearing proof-of-concept studies.
Implementation:
- Discussions covered a range of investigational drugs, including T-1249, Reverset, UK-427857, L-870810, PA-457, remofovir, and VX-950.
- Emerging technologies were presented as potential platforms for future antiviral therapeutics.
Implications:
- The summit underscored a concentrated effort on developing novel HIV treatments.
- Advancements in hepatitis C therapeutics suggest promising near-term clinical validation and potential breakthroughs.